Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences.
about
Selective serotonin reuptake inhibitors for fibromyalgia syndromeAntipsychotics for fibromyalgia in adultsCannabinoids for chronic neuropathic painIdentifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results.Long-term opioid use in non-cancer pain.Interpretability of the PedsQL™ Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in Pediatric Patients With Functional and Organic Gastrointestinal Diseases.Does Future Diabetes Risk Impair Current Quality of Life? A Cross-Sectional Study of Health-Related Quality of Life in Relation to the Finnish Diabetes Risk Score (FINDRISC).Efficacy, acceptability and safety of guided imagery/hypnosis in fibromyalgia - A systematic review and meta-analysis of randomized controlled trials.Patient-reported questionnaires in MS rehabilitation: responsiveness and minimal important difference of the multiple sclerosis questionnaire for physiotherapists (MSQPT).Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments.Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials.Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults.[Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores.Mapping the disease-specific LupusQoL to the SF-6D.Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.Estimating the minimum important change in the 15D scores.Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome - A systematic review and meta-analysis of randomized controlled trials.Systematic review and meta-analysis of cannabinoids in palliative medicine.Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.[Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].[Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration].Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease.Important differences and meaningful changes for the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)
P2860
Q24187263-7719E9FB-9773-4F3C-B333-A1C734BA724DQ26471557-6E6170C9-2D0C-415B-B1CA-2B9BCB2A4584Q26472068-B11309C9-A6C2-4E30-BC95-240DD523AAFEQ33768737-D2E2E156-C3FC-4366-9C16-BECA3911E39AQ34547022-29BFB154-F683-4409-99E4-8962AF18C706Q35749754-AE91BCEC-FA83-4D1C-B581-6F48948FC5B6Q35913145-C81DD0CD-1437-4FC8-B3F7-A2F0DA74CB49Q36206470-82BBDA2B-446F-4861-8881-73147B5E3E8EQ36311180-F61B96C1-FD96-46E0-9D30-A3923EDC0A3EQ37217253-ABAA7856-EAC2-4459-87BF-39ADCAD348D5Q38595582-8E2D136D-0A8D-4074-A13E-7A210F7B9A30Q38696763-3B5CCB00-8DB0-4FE9-B1BC-23A14F52D5E0Q38871845-113B0C63-39B5-435B-9EB4-5BB6DE183A89Q39177606-3DE6D972-6CA1-4C46-B895-BAE7ECE3E1C0Q39377617-C9E0EE29-A24D-4E53-97B3-04DCB253BAC6Q41687005-8092832E-B473-4FA6-B34B-6F9A50E1292AQ46235212-1C418FAB-34DA-42E3-8657-1966648DB63EQ46526564-62E97C3B-3DD3-4BF5-8E17-7973A624ED6EQ47604790-81D77D57-222E-466D-8755-BC3AC80F6360Q50201189-22A2BFAB-8151-4373-87B1-1A77F6109C70Q52681690-6362455C-2F37-4C72-86DD-3A8899979536Q53637692-80062C45-74AE-4D35-9E51-F819CEA5FB41Q53686451-063EED98-0725-48E0-AAF7-8E1858BAE573Q55379461-67095C47-CAED-4C0D-9F66-94BE56813B0EQ58964778-D680ED19-A148-4918-92FD-80F22337D8F1
P2860
Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Don't middle your MIDs: regres ...... nimally important differences.
@en
Don't middle your MIDs: regres ...... nimally important differences.
@nl
type
label
Don't middle your MIDs: regres ...... nimally important differences.
@en
Don't middle your MIDs: regres ...... nimally important differences.
@nl
prefLabel
Don't middle your MIDs: regres ...... nimally important differences.
@en
Don't middle your MIDs: regres ...... nimally important differences.
@nl
P2860
P1476
Don't middle your MIDs: regres ...... inimally important differences
@en
P2093
Ron D Hays
P2860
P2888
P356
10.1007/S11136-013-0443-4
P577
2013-05-31T00:00:00Z